Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.43 |
| ▸ | GRM5 | P41594 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | KDM4A | O75164 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.41 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19196710 | 0.93 | KMT2A (0.43) | SMN1; SMN2KMT2ANPC1RAB9ANR1H2 | |
| SCHEMBL19195940 | 0.90 | NR3C1 (0.49) | SMN1; SMN2 | |
| SCHEMBL19195922 | 0.90 | SMN1; SMN2 (0.51) | SMN1; SMN2KMT2AKDM4ANPC1RAB9A | |
| SCHEMBL19196224 | 0.87 | RXFP1 (0.42) | RXFP1APOBEC3GGRM5NPC1RAB9A | |
| SCHEMBL17336927 | 0.85 | SMN1; SMN2 (0.50) | SMN1; SMN2KMT2A | |
| SCHEMBL17336619 | 0.85 | KMT2A (0.48) | SMN1; SMN2GRM5KMT2A | |
| SCHEMBL17336858 | 0.84 | AHR (0.42) | SMN1; SMN2KMT2ANPC1RAB9A | |
| SCHEMBL19195942 | 0.83 | KDM4A (0.46) | SMN1; SMN2KMT2AKDM4ANPC1RAB9A | |
| SCHEMBL2339443 | 0.81 | SMN1; SMN2 (0.59) | SMN1; SMN2KDM4ANPC1RAB9ANR1H2 | |
| SCHEMBL29035858 | 0.81 | NPC1 (0.55) | SMN1; SMN2KMT2ANPC1RAB9ANR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9969726-B2 | Metabotropic glutamate receptor negative allosteric modulators (NAMS) and uses thereof | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2018-05-15 | — | — | US | disclosed |
| US-20170217951-A1 | Metabotropic Glutamate Receptor Negative Allosteric Modulators (NAMS) and Uses Thereof | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2017-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170217951-A1 | Metabotropic Glutamate Receptor Negative Allosteric Modulators (NAMS) and Uses Thereof | GRM3, GRM2, GRM1 | SMN1; SMN2 1357/4885RXFP1 737/4885APOBEC3G 3202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.